NEW YORK (GenomeWeb News) — BioMérieux and ExonHit Therapeutics plan to develop a blood-based prostate-cancer screening test aimed at helping doctors weigh the risks of performing surgery to remove tumors, BioMérieux said yesterday.

 

Under the collaboration, BioMérieux will use ExonHit’s genome expression IP to develop DNA chips that can detect “several dozens of nucleic acid markers” and use them to find cancer markers in blood.

 

Financial terms of the agreement were not released.